Benzinga | Nov 6, 2020 10:37AM EST

SVB Leerink Maintains Underperform on Clovis Oncology, Lowers Price Target to $3

SVB Leerink maintains Clovis Oncology (NASDAQ:CLVS) with a Underperform and lowers the price target from $4 to $3.